Oligomerix
A global pharmaceutical executive, Mr. Micati worked at Pfizer Inc. for 34 years. He was a member of Pfizer’s 10-member Corporate Management Committee responsible for all aspects of global operations. One of his numerous accomplishments was in-licensing donepezil (Aricept) from Eisai which today is the number one selling drug for Alzheimer’s disease. He also served as Executive Vice President of the Pharmaceutical group and Vice President of Pfizer Inc., and was responsible for Pfizer’s European pharmaceutical operations and Global Consumer Health Care group. He was appointed to the International Board of Directors in 1984 and became President of Pfizer’s European operations in 1990.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Oligomerix
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer’s disease and related dementias by targeting tau self-association. The company’s drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program. Oligomerix’s small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.